Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for FaDu Cells (Hypopharyngeal Carcinoma Cells)
- Proprietary cationic lipids formulation
- High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
- Effective and robust intracellular delivery
- Kit includes Transfection Enhancer reagent
- Work in the presence of serum
- A proven reagent for establishing stable cell lines
- Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download FaDu CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for FaDu cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems FaDu Transfection Protocol: [PDF]
Download MSDS: [PDF]
FaDu Cell Line:
Hypopharyngeal cancer is a disease where cancerous cells develop in the lower part of the throat, particularly in the lining of the hypopharynx, which is usually detected at an advanced stage because of the absence of early symptoms. According to the researchers at Harvard Medical School, people who smoke and have a vitamin A deficiency are more likely to develop pharyngeal cancer, or as it is commonly known, throat cancer. Transfection studies carried out via cancer cell lines can help determine novel biochemical pathways that can retard the growth of cancerous tumors. The FaDu throat cancer cell line was derived from a hypopharyngeal tumor of a 56-year old Hindi Caucasian male. FaDu cell lines have been known to produce proinflammatory cytokines and activate neutrophils in vitro, along with HT-29 cell line. In addition to being an appropriate transfection host for various cellular and molecular biology applications, the FaDu cell line is commonly utilized in the study of pharyngeal squamous-cell carcinoma. Altogen Biosystems offers lipid-based high-efficiency transfection reagent kits for the FaDu hypopharyngeal carcinoma cell line.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in FaDu cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in FaDu cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into FaDu cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #1753)
- 1.5 ml (Catalog #1754)
- 1.5 ml CRISPR (Catalog #2141)
- 8.0 ml (Catalog #7039)